Immune response after two doses of the BNT162b2 COVID-19 vaccine and risk of SARS-CoV-2 breakthrough infection in Tyrol, Austria: an open-label, observational phase 4 trial

https://www.thelancet.com/journals/lanmic/article/PIIS2666-5247(23)00107-6/fulltext?dgcid=hubspot_email_covidalerts&utm_campaign=covidalerts&utm_medium=email&_hsmi=268172138&_hsenc=p2ANqtz-8WU0dLX4sPjXmtnxnMjeA7nwdmuCCYs2TfzA7EbObD9S1usNUidoEzSQCVRsLwCcgixTaCqXqSxSJaZhryx54LfOsGKA&utm_content=268146206&utm_source=hs_email